VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
VX1.DE Key Statistics, Chart & Performance
The current stock price of VX1.DE is 376.45 EUR. In the past month the price increased by 1.98%. In the past year, price decreased by -13.62%.
VX1.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.42 | 49.44B | ||
| ARGX.BR | ARGENX SE | 74.18 | 49.28B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.32B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.99B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.94B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.75B | ||
| 5CV.DE | CUREVAC NV | 5.11 | 1.00B | ||
| NANO.PA | NANOBIOTIX | N/A | 877.52M | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 505.40M | ||
| ALCLS.PA | CELLECTIS | N/A | 411.83M | ||
| FYB.DE | FORMYCON AG | N/A | 409.06M |
Related stock screener links
About VX1.DE
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What does VERTEX PHARMACEUTICALS INC do?
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
What is the stock price of VERTEX PHARMACEUTICALS INC today?
The current stock price of VX1.DE is 376.45 EUR. The price increased by 0.8% in the last trading session.
Does VX1 stock pay dividends?
VX1.DE does not pay a dividend.
What is the ChartMill rating of VERTEX PHARMACEUTICALS INC stock?
VX1.DE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the GICS sector and industry of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for VX1 stock?
The PE ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 24.98. This is based on the reported non-GAAP earnings per share of 15.07 and the current share price of 376.45 EUR.
Can you provide the market cap for VERTEX PHARMACEUTICALS INC?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a market capitalization of 96.52B EUR. This makes VX1.DE a Large Cap stock.
VX1.DE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to VX1.DE. When comparing the yearly performance of all stocks, VX1.DE is a bad performer in the overall market: 68.86% of all stocks are doing better.
VX1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE. VX1.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
VX1.DE Financial Highlights
Over the last trailing twelve months VX1.DE reported a non-GAAP Earnings per Share(EPS) of 15.07. The EPS increased by 3303.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.35% | ||
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| Debt/Equity | 0 |
VX1.DE Forecast & Estimates
39 analysts have analysed VX1.DE and the average price target is 430.81 EUR. This implies a price increase of 14.44% is expected in the next year compared to the current price of 376.45.
For the next year, analysts expect an EPS growth of 6237.82% and a revenue growth 10.08% for VX1.DE